- Trade Name: Seysara (Allergan)
- Indications: indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
- Class: Antibiotic, Antibiotic; tetracycline
- Half-life: 21–22 hours
- FDA Approval Date: 10/01/2018
- Clinically important, potentially hazardous interactions with:
Acitretin, Isotretinoin - Pregnancy: may cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
